MGC Pharmaceuticals Ltd's (ASX:MXC) Roby Zomer tells Proactive's Andrew Scott they have two investigational medicinal products targeting epilepsy and dementia as well as Alzheimer’s disease. These include CannEpil®, an oral oil solution treatment for refractory epilepsy and CogniCann®, an oral spray for relief of dementia symptoms. MGC's also recently confirmed the effective immunological activity for the use of another one of their products - ArtemiC - as an immune-modulatory agent for the treatment of COVID-19. They're currently awaiting the first interim results from the COVID-19 infected patients from the Phase II randomised, double-blind clinical trial which is taking place in Israel with an additional site in India.
MGC Pharmaceuticals combining science and cannabis to create 'affordable medicines'
Quick facts: MGC Pharmaceuticals Ltd
Price: - -
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE